New drug approvals and encouraging pipeline progress should sustain momentum in the Zacks Biomedical & Genetics industry despite uncertain macro conditions. A strong portfolio and solid pipeline progress position TERN, ADMA, ANIP and LQDA to potentially outperform peers in this volatile sector.
New drug approvals and encouraging pipeline progress should sustain momentum in the Zacks Biomedical & Genetics industry despite uncertain macro conditions. A strong portfolio and solid pipeline progress position TERN, ADMA, ANIP and LQDA to potentially outperform peers in this volatile sector.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
